Today: 10 June 2026
Palantir (PLTR) stock slides 5.6% as insider sale notice surfaces — what to watch next week
4 January 2026
1 min read

Palantir (PLTR) stock slides 5.6% as insider sale notice surfaces — what to watch next week

NEW YORK, Jan 4, 2026, 13:28 ET — Market closed

  • Palantir ended Friday down about 5.6% at $167.86, lagging a near-flat Nasdaq session.
  • A post-close SEC filing showed officer Ryan D. Taylor filed a Form 144 to sell up to 12,000 shares under a 10b5-1 plan.
  • Markets reopen Monday with Jan. 9 U.S. jobs data and Jan. 13 CPI in focus; Palantir’s next results are penciled in for early February on earnings calendars.

Palantir Technologies Inc shares closed down about 5.6% on Friday at $167.86, their first session of 2026, after swinging from an early high near $183 to a low around $166.

Why this matters now: the selloff leaves Palantir starting the week under a spotlight as investors return from the holidays and reassess risk in high-growth software names alongside a heavy macro calendar. “The market is looking for direction,” said Matthew Maley, chief market strategist at Miller Tabak, as traders eye whether stocks break out of recent ranges. Reuters

The first full trading week also brings U.S. employment data on Jan. 9 and consumer inflation data on Jan. 13, both potential swing factors for interest-rate expectations that tend to drive sentiment toward growth stocks. Fed funds futures suggest little chance of a rate cut at the central bank’s late-January meeting, with roughly a 50% chance of a quarter-point cut in March, Reuters reported.

After Friday’s closing bell, an SEC filing showed Palantir officer Ryan Douglas Taylor filed a Form 144 — a notice used by insiders planning to sell stock under SEC Rule 144 — to sell up to 12,000 shares valued at about $2.13 million through Morgan Stanley Smith Barney. The form cited a 10b5-1 plan, a pre-set trading schedule that allows executives to sell shares automatically.

The same filing listed earlier sales in late November totaling 56,061 shares for about $9.1 million in gross proceeds, underscoring the steady stream of insider supply investors will weigh into Monday’s open.

Palantir, known for software that helps organizations analyze large data sets, has drawn outsized attention from traders because its shares have been prone to sharp moves when sentiment shifts on “AI trade” positioning and rate expectations.

For the next catalyst on the company side, Palantir last guided fourth-quarter revenue to $1.327 billion to $1.331 billion, according to a company statement, a bar investors will use to frame expectations heading into the next report.

But the downside case for the stock is straightforward: hotter inflation or firmer jobs data could push bond yields higher and squeeze richly valued growth shares, while additional insider filings can add to near-term supply just as liquidity returns after the holidays.

Earnings calendars on Nasdaq and Yahoo Finance currently point to Feb. 2 for Palantir’s next report, though the company has not posted an announced date on its investor events page.

Stock Market Today

  • CF Industries Shares Pullback Presents Potential Value Opportunity, DCF Model Shows
    June 10, 2026, 5:58 PM EDT. CF Industries Holdings (CF) shares have slid 4.3% over the past week and 5.6% in the last month, yet maintain a strong 35.5% gain year-to-date. The nitrogen fertilizer producer is influenced by global agricultural demand and commodity costs. A Discounted Cash Flow (DCF) valuation suggests CF is trading at a 33.6% discount to its intrinsic value of $163.43 per share, currently priced around $108.58. This analysis signals potential undervaluation amid a complex commodity market backdrop. Investors may consider this alongside ongoing sector risks such as food security and capital expenditure trends.

Latest articles

Parabilis Medicines (PBLS) soars 58% after $670 million IPO beats range

Parabilis Medicines (PBLS) soars 58% after $670 million IPO beats range

10 June 2026
Parabilis Medicines soared 58% above its $20 IPO price to close at $31.60 in its Nasdaq debut after raising a record $670 million, reflecting strong investor demand for its Helicon drug platform ahead of a pivotal Phase 3 desmoid tumor trial planned for 2027; Regeneron’s $75 million private placement added credibility.
Joby Aviation Shares Slip After CFO Files to Sell Stock

Joby Aviation Shares Slip After CFO Files to Sell Stock

10 June 2026
Joby Aviation fell 4.47% to $8.86 after CFO Rodrigo Brumana disclosed selling 78,489 shares under a prearranged 10b5-1 plan, with no new certification or commercial-launch updates, leaving investors focused on regulatory progress and cash burn as the key catalysts for the stock.
YY Group Shares Spike as Humanoid Robot Plans Unveiled

YY Group Shares Spike as Humanoid Robot Plans Unveiled

10 June 2026
YY Group Holding shares surged to $0.165 on heavy volume after announcing a commercial humanoid-robotics initiative using Unitree G1 robots and facility-management data, reframing the company as a robotics-and-AI data play; the rally comes despite 2025 net loss, dilution risk from a relaunched at-the-market share-sale program, and no disclosed robot-related revenue or contracts.
Tesco issues urgent “do not eat” recall for three pate lines after date-label error
Previous Story

Tesco issues urgent “do not eat” recall for three pate lines after date-label error

Chevron caught in Venezuela oil clamp as PDVSA cuts output under U.S. embargo
Next Story

Chevron caught in Venezuela oil clamp as PDVSA cuts output under U.S. embargo

Go toTop